Annovis Bio, Inc. (ANVS)

NYSE: ANVS · Real-Time Price · USD
1.650
-0.200 (-10.81%)
At close: Mar 28, 2025, 4:00 PM
1.679
+0.029 (1.78%)
After-hours: Mar 28, 2025, 4:21 PM EDT
Market Cap 32.15M
Revenue (ttm) n/a
Net Income (ttm) -24.59M
Shares Out 19.49M
EPS (ttm) -2.31
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 402,941
Open 1.700
Previous Close 1.850
Day's Range 1.630 - 1.740
52-Week Range 1.530 - 20.000
Beta 1.65
Analysts Strong Buy
Price Target 37.00 (+2,142.42%)
Earnings Date Mar 21, 2025

About ANVS

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company’s lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer’s disease (AD), Parkinson’s disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally ... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jan 29, 2020
Employees 16
Stock Exchange NYSE
Ticker Symbol ANVS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 5 analysts, the average rating for ANVS stock is "Strong Buy." The 12-month stock price forecast is $37.0, which is an increase of 2,142.42% from the latest price.

Price Target
$37.0
(2,142.42% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Annovis Bio, Inc. Receives Continued Listing Standard Notice From the NYSE

MALVERN, Pa., March 27, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurod...

1 day ago - GlobeNewsWire

Annovis to Attend AD/PD™ 2025 with Extensive Scientific Program

MALVERN, Pa., March 25, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseas...

3 days ago - GlobeNewsWire

Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

MALVERN, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurode...

6 days ago - GlobeNewsWire

Annovis Joins Experts at Drug Development Summit to Redefine Parkinson's Treatment

MALVERN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseas...

17 days ago - GlobeNewsWire

Annovis to Host Patients' Live Forum on February 27, 2025

MALVERN, Pa., Feb. 19, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS)  ("Annovis" or the "Company"), a clinical-stage drug platform company developing novel therapies for neurodegen...

5 weeks ago - GlobeNewsWire

Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference

MALVERN, Pa., Feb. 07, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies fo...

7 weeks ago - GlobeNewsWire

Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer's Disease

MALVERN, Pa., Feb. 05, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies fo...

7 weeks ago - GlobeNewsWire

Annovis Bio, Inc. Announces Closing of $21 Million Public Offering

MALVERN, PA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- via IBN - Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies fo...

7 weeks ago - GlobeNewsWire

Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering

MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies f...

7 weeks ago - GlobeNewsWire

Annovis Bio, Inc. Announces Proposed Public Offering

MALVERN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies f...

7 weeks ago - GlobeNewsWire

Annovis Granted U.S. Patent for Treatment and Prevention of Acute Brain or Nerve Injuries Securing Global Protection

MALVERN, Pa, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodege...

2 months ago - GlobeNewsWire

Annovis CEO Showcases Groundbreaking Advances in Neurodegenerative Disease Treatment on Today's Marketplace

LOS ANGELES, Dec. 05, 2024 (GLOBE NEWSWIRE) -- via IBN -- InvestorBrandNetwork, a multifaceted communications organization engaged in connecting public companies to the investment community, is please...

4 months ago - GlobeNewsWire

/C O R R E C T I O N -- Today's Marketplace/

In the news release, Annovis CEO Discusses Breakthrough Drug for Neurodegenerative Diseases on Today's Marketplace, issued 04-Dec-2024 by Today's Marketplace over PR Newswire, we are advised by the co...

4 months ago - PRNewsWire

Annovis to Host Year-End Investor Webcast on December 11, 2024

MALVERN, Pa., Nov. 25, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, is pleased t...

4 months ago - GlobeNewsWire

IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Maria Maccecchini, CEO of Annovis Bio

LOS ANGELES, Oct. 31, 2024 (GLOBE NEWSWIRE) -- via IBN -- IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the...

5 months ago - GlobeNewsWire

FDA Clears Annovis to Launch Pivotal Phase 3 Alzheimer's Studies, Paving the Way to NDAs

MALVERN, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing transformative therapies fo...

5 months ago - GlobeNewsWire

Annovis Bio Inc. (NYSE: ANVS) Leading Way in Development of Safe, Effective Drugs for Neurodegenerative Diseases

NEW YORK, Oct. 03, 2024 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Annovis Bio Inc. (NYSE: ANVS) announces the availability of a broadcast titled, “Transforming Alzheimer's Treatment: Innovative Combinati...

6 months ago - GlobeNewsWire

Annovis Bio Inc. (NYSE: ANVS) Research Points to Potential Future Breakthroughs in AD Space Through Innovative Combinations

NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- via InvestorWire — Annovis Bio Inc. (NYSE: ANVS) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ brands withi...

6 months ago - GlobeNewsWire

Annovis Bio (NYSE: ANVS) to Present at H.C. Wainwright 26th Annual Global Investment Conference

MALVERN, Pa., Sept. 05, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company developing novel therapies for neurod...

7 months ago - GlobeNewsWire

Annovis' Lead Compound Enhances Cognition Synergistically with GLP-1 Agonist

MALVERN, Pa., Aug. 06, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies fo...

8 months ago - GlobeNewsWire

Annovis Bio Secures U.S. Patent for Treatment of Acute Traumatic Brain Injury with Buntanetap

MALVERN, Pa., July 24, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies fo...

8 months ago - GlobeNewsWire

Annovis stock more than doubled on Tuesday: what happened?

Shares of Annovis Bio Inc (NYSE: ANVS) more than doubled on Tuesday after the biotech firm reported positive late-stage data for buntanetap. Buntanetap is the candidate treatment of ANVS for Parkinson...

9 months ago - Invezz

Annovis Bio's stock rockets 119% after reporting positive data in Parkinson's disease trial

Annovis Bio Inc.'s stock rocketed 119% on Tuesday after the biotech reported positive results in a late-stage trial of its Parkinson's disease treatment called buntanetap.

9 months ago - Market Watch

Annovis Bio Files Patent for New Composition of Matter for Buntanetap

MALVERN, Pa., June 26, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies fo...

9 months ago - GlobeNewsWire

Annovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients

MALVERN, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage drug platform company developing novel therapies for neurodegenerativ...

10 months ago - GlobeNewsWire